This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

The U.S. FDA-approved  Telmisartan +Amlodipine + chlorthalidone for treating hypertension on  November 16, 2009. Telmisartan+ Amlodipine + chlorthalidone belongs to the group of medications called antihypertensives.

Mechanism of Action of undefined

This medication consists of a combination of two medicines, Telmisartan and Amlodipine + chlorthalidone. Telmisartan is the angiotensin receptor blocker, and Amlodipine + chlorthalidone is the calcium channel blocker. They work by relaxing the blood vessels and making the heart-pumping action efficient. The combination of both Telmisartan and Angiotensin lowers blood pressure efficiently.

Uses of undefined

Telmisartan +Amlodipine + chlorthalidone is primarily used for the treatment of hypertension. Hypertension (high blood pressure) is a medical condition in which blood exerts a force on the artery walls (blood vessels), resulting in heart disease, irregular heartbeat, and other problems. This medicine helps to relax the blood vessels by making it easier for the heart to pump blood all over the body, and it lowers the risk of heart attack and stroke.

undefined Drug administaration and Dosage available

Take the  Telmisartan +Amlodipine + chlorthalidone as your physician advises. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

Warnings, Precautions and Side Effects of undefined

Warnings

Do not consume this medicine if you are hypersensitive to Telmisartan, Amlodipine + chlorthalidone, or dihydropyridine derivatives. It should not be used in women beyond the third trimester of pregnancy, patients with severe liver or bile problems. Notify your doctor if you have shock, left-sided heart blood flow obstruction, or heart failure after a heart attack. 

Precautions

It should also not be combined with aliskiren-containing medications in patients with type 2 diabetes or moderate to severe kidney impairment. Dose adjustment will be needed ins such conditions. While using this medication, blood pressure should be monitored regularly, and a kidney function test should be performed to note if there are any abnormal changes. It is unsafe to consume alcohol while taking Telmisartan + Amlodipine + chlorthalidone. Please speak with your physician. Also, Telmisartan + Amlodipine + chlorthalidone could alter the driving ability or operating machinery capacity by causing dizziness, headaches, nausea, and tiredness.

Side Effects

The most common side effects of  Telmisartan +Amlodipine + chlorthalidone are sleepiness, ankle swelling, nausea, headache, flushing, dizziness, fatigue (tiredness), palpitations, stomach upset, peripheral edema, and mood changes.

Word Of Advice

It is suggested to inform your doctor if you have a history of allergic reactions to Telmisartan + Amlodipine + chlorthalidone to avoid life-threatening complications. Do not use this medicine if you have a history of heart disease (angina, myocardial infarction, stroke, or transient ischemic attack). Tell your doctor before the treatment commencement if you are pregnant or having liver, kidney, or uterine problems. While using this medication, blood pressure should be monitored regularly, and a kidney function test should be performed to note if there are any abnormal changes.

Frequently Asked Question

References

  1. KD Tripathi, Essentials of Medical Pharmacology, Antihypertensive drugs, 7th edition. 2013, 561-563.
  2. Boehringer Ingelheim Pharmaceuticals, Inc., US Food and Drug Administration, [Revised on October 2011] [Accessed date 9th June 2023] Twynsta (telmisartan/Amlodipine + chlorthalidone) tablet label (fda.gov)
  3. European medicines agency,  [Revised on 10th January 2022] [Accessed date 9th June 2023] Twynsta | European Medicines Agency (europa.eu)

Disclaimer

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.